Tag

Generics

All articles tagged with #generics

business21 days ago•327 min saved

India set to drive down Ozempic-like drug costs as semaglutide patent nears expiry

As Novo Nordisk’s semaglutide patent nears expiry in March, Indian pharma companies are ramping up generic production of semaglutide injections (and competitors like tirzepatide), with price expectations falling from hundreds of dollars per month to about $77 initially and potentially around $40 over time. Analysts say this could trigger a global price war and transform India into a major low-cost supplier for obesity and diabetes treatments, though experts warn against misuse and stress the need for lifestyle interventions alongside medication.

via cnn.com|

#business #generics #india

health-policy21 days ago•3 min saved

TrumpRx Promises the Cheapest Drugs, Yet Generics Undercut Many Offers

STAT found that TrumpRx markets deep cash discounts for about 43 brand-name drugs, but at least 18 of them have cheaper generics available on GoodRx or Cost Plus Drugs; TrumpRx only displays cash prices and does not sell medicines directly, highlighting that many savings come from generic options rather than the site’s claims.

via statnews.com|

#drug-pricing #generics #health-policy

healthcare23 days ago•1 min saved

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

via Axios|

#costplusdrugs #drug-pricing #generics

business2 years ago•2 min saved

Novartis' Sandoz spin-off achieves successful market debut at 24 Swiss francs

Novartis has completed the spinoff of its generics and biosimilars business, Sandoz, with shares trading at 24 Swiss francs on the SIX Swiss Exchange. The move is part of Novartis' strategy to focus on its patented prescription medicines. Sandoz, now an independent company, aims to deepen its impact on patients and society, with a focus on expanding its generics and biosimilars business, driving sales growth, and increasing profit margins. The company has a pipeline of 25 biologics projects, with plans to launch five more over the next two years. Around half of Sandoz's revenues come from Europe, and it expects significant growth in North America.

via CNBC|

#business #generics #novartis

health2 years ago•9 min saved

Shortage of Cancer Drugs Leaves US Patients in Crisis

Shortages of generic drugs, including 12 cancer drugs, are causing rationing and delays in cancer treatment for patients in the US. The underlying weakness of the generic drug industry, which is made mostly overseas and often sold at a loss or for little profit, is the main cause. Domestic manufacturers have little interest in making them, setting their sights instead on high-priced drugs with plump profit margins. The FDA has given emergency authorization for Chinese-made cisplatin to enter the US market, but the impact of the move wasn’t immediately clear.

via Kaiser Health News|

#cancer #drug-shortage #fda

health2 years ago•2 min saved

EU's proposed drug laws overhaul sparks industry backlash.

The European Union has published a draft of its proposed overhaul of laws governing the pharmaceuticals industry, which is aimed at ensuring all Europeans have access to both innovative new treatments and generic drugs, and ending huge divergences in access and price between countries. The biggest overhaul of existing medical laws in two decades proposes to cut the length of basic market exclusivity that drugmakers get before generics can enter the market to eight from 10 years. However, the pharma industry warns it will invest and innovate elsewhere, while patient groups cheer the win for people against big pharma.

via Reuters|

#drugmakers #eu #generics